Dr. Roy S. Herbst Discusses Immunotherapy in Squamous and Nonsquamous NSCLC

Roy S. Herbst, MD, PhD, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, discusses immunotherapy in squamous and nonsquamous non-small cell lung cancer (NSCLC).

Herbst says it is quite clear that immunotherapy is becoming a new paradigm to treat these tumors. In squamous cell disease, it has risen to the second-line setting, with other trials looking at targeted therapies and combinations afterwards. The data are less clear in the nonsquamous area, however, due to the potential importance of a biomarker.

Roy S. Herbst, MD, PhD, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, discusses immunotherapy in squamous and nonsquamous non-small cell lung cancer (NSCLC). Herbst elaborates on presentations and current treatments discussed at the 17th Annual International Lung Cancer Congress® in Huntington Beach, California.